Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 12/20 | 1.00 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 1.00 |
| ▸ | TRPC1 | P48995 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16028598 | 0.98 | TRPC5 (0.95) | TRPC5TRPC4TRPC1KCNH2TSHR | |
| SCHEMBL16028243 | 0.97 | TRPC5 (0.94) | TRPC5TRPC4TRPC1KCNH2TSHR | |
| SCHEMBL16029036 | 0.95 | TRPC5 (0.91) | TRPC5TRPC4TRPC1KCNH2TSHR | |
| SCHEMBL16363508 | 0.94 | TRPC5 (0.89) | TRPC5TRPC4TRPC1KCNH2TSHR | |
| SCHEMBL16028242 | 0.93 | TRPC5 (0.88) | TRPC5TRPC4TRPC1KCNH2TSHR | |
| SCHEMBL16027988 | 0.93 | TRPC5 (0.88) | TRPC5TRPC4TRPC1KCNH2TSHR | |
| SCHEMBL16027656 | 0.93 | TRPC5 (0.88) | TRPC5TRPC4TRPC1KCNH2TSHR | |
| SCHEMBL16028620 | 0.93 | TRPC5 (0.88) | TRPC5TRPC4TRPC1KCNH2TSHR | |
| SCHEMBL16028439 | 0.93 | TRPC5 (0.86) | TRPC5TRPC4TRPC1KCNH2TSHR | |
| SCHEMBL16076122 | 0.93 | TRPC5 (0.86) | TRPC5TRPC4TRPC1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661847-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE | Boehringer Ingelheim International GmbH (DE) | 2025-12-17 | — | — | EP | claimed |
| WO-2024236027-A1 | 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE FOR USE IN THE TREATMENT OF BORDERLINE PERSONALITY DISORDER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-21 | — | — | WO | claimed |
| WO-2024165540-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-15 | — | — | WO | claimed |
| US-9969736-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2018-05-15 | — | — | US | claimed |
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-26 | — | — | US | claimed |
| US-12624041-B2 | Heterocyclic compound and use thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-4661847-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE | Boehringer Ingelheim International GmbH (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661847-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE | Boehringer Ingelheim International GmbH (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4661847-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE | Boehringer Ingelheim International GmbH (DE) | 2025-12-17 | — | — | EP | disclosed |
| EP-4638452-A1 | PROCESS FOR THE PREPARATION OF 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE | Boehringer Ingelheim International GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638452-A1 | PROCESS FOR THE PREPARATION OF 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE | Boehringer Ingelheim International GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638452-A1 | PROCESS FOR THE PREPARATION OF 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE | Boehringer Ingelheim International GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-2970303-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | Hydra Biosciences, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014143799-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014143799-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014143799-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143799-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624041-B2 | Heterocyclic compound and use thereof | TRPC1, TRPC5, TRPC3 | TRPC5 2/4885TRPC4 7/4885TRPC1 1/4885 |
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | TRPC5, TRPC7, TRPC4 | TRPC5 1/4885TRPC4 3/4885TRPC1 4/4885 |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | TRPC5 1/4885TRPC4 3/4885TRPC1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.